-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
BridgeBio Pharma, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2018 to Q2 2024.
- BridgeBio Pharma, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$176M, a 20.2% decline year-over-year.
- BridgeBio Pharma, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$510M, a 3.83% increase year-over-year.
- BridgeBio Pharma, Inc. annual Operating Income (Loss) for 2023 was -$607M, a 18.6% decline from 2022.
- BridgeBio Pharma, Inc. annual Operating Income (Loss) for 2022 was -$512M, a 11.2% increase from 2021.
- BridgeBio Pharma, Inc. annual Operating Income (Loss) for 2021 was -$577M, a 21.5% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)